Sign In
Buy RCKT
$3.11
-0.100 (-3.12%)
At Close: Jul 31, 2026
Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)
11:50am, Friday, 05'th Apr 2024
Rocket Pharmaceuticals, Inc. has potential FDA approvals for its gene therapies on the horizon. The company focuses on developing gene therapies for rare diseases, targeting a market that is expected
EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia
12:36pm, Wednesday, 03'rd Apr 2024
The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.
Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch
02:34pm, Tuesday, 02'nd Apr 2024
EMA accepted Rocket Pharmaceuticals, Inc. regulatory application of RP-L102 for the treatment of patients with Falconi Anemia. A U.S. FDA BLA filing of RP-L102 for the treatment of patients with Falco
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report?
12:36pm, Wednesday, 27'th Mar 2024
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock?
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Rocket Pharmaceuticals' Promising Path In Gene Therapy
06:03pm, Friday, 01'st Mar 2024
Rocket Pharmaceuticals, Inc. stock surged 76% post a "Buy" recommendation, fueled by positive Phase 2 trial news for RP-A501 in Danon disease. RP-A501, targeting a rare disease without current treatme
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4
01:21pm, Tuesday, 27'th Feb 2024
Rocket Pharmaceuticals' (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
04:01pm, Monday, 26'th Feb 2024
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
7 Speculative Stocks to Double Your Money THIS Year
10:14pm, Monday, 22'nd Jan 2024
While investors should probably direct the majority of their market-earmarked funds toward slow-and-steady ideas – à la Warren Buffett – sometimes, we end up with gambling money. And in that case
Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
04:01pm, Tuesday, 02'nd Jan 2024
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
07:00am, Tuesday, 12'th Dec 2023
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare
Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates
12:47pm, Wednesday, 15'th Nov 2023
Rocket (RCKT) gains 40% in three months on positive regulatory updates on its key candidates.
Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?
11:17am, Thursday, 09'th Nov 2023
The consensus price target hints at a 167.1% upside potential for Rocket Pharmaceuticals (RCKT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea
